Literature DB >> 18238883

Antimicrobial policies in the neonatal units of the United Kingdom and Republic of Ireland.

Andrew Michael Russell Fernando1, Paul Trafford Heath, Esse Natasha Menson.   

Abstract

OBJECTIVES: To review antibiotic and antifungal policies in British and Irish neonatal units (NNUs).
METHODS: A telephone survey was performed regarding empirical antimicrobial guidelines of NNUs in the UK and Republic of Ireland.
RESULTS: The response rate was 91% (202 of 222 NNUs). The guidelines from all responding units covered group B Streptococcus and Escherichia coli, the most common causes of neonatal septicaemia and meningitis. However, 19% did not cover Listeria, the cause of meningitis in 5% to 7% of cases in England and Wales. Second-line recommendations varied greatly between units, with widespread use of broad-spectrum agents. Fungal prophylaxis and treatment guidelines were generally rudimentary.
CONCLUSIONS: Empirical antimicrobial recommendations on many NNUs include broad-spectrum antibiotics without ensuring universal coverage of important pathogens. We raise concerns about the selection pressures exerted for resistant pathogens and invasive fungal disease, especially as few units specify fungal prophylaxis or treatment guidance. Development of rational guidelines for the UK and Irish neonatal units might help to optimize treatment while minimizing overuse of broad-spectrum agents.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18238883     DOI: 10.1093/jac/dkm543

Source DB:  PubMed          Journal:  J Antimicrob Chemother        ISSN: 0305-7453            Impact factor:   5.790


  7 in total

1.  Off-label antibiotic use in children in three European countries.

Authors:  Alessandro Porta; Susanna Esposito; Esse Menson; Nikos Spyridis; Maria Tsolia; Mike Sharland; Nicola Principi
Journal:  Eur J Clin Pharmacol       Date:  2010-06-08       Impact factor: 2.953

2.  Administration of capsule-selective endosialidase E minimizes upregulation of organ gene expression induced by experimental systemic infection with Escherichia coli K1.

Authors:  Andrea Zelmer; Melissa J Martin; Ozan Gundogdu; George Birchenough; Rebecca Lever; Brendan W Wren; J Paul Luzio; Peter W Taylor
Journal:  Microbiology (Reading)       Date:  2010-04-15       Impact factor: 2.777

3.  Current management of late onset neonatal bacterial sepsis in five European countries.

Authors:  Irja Lutsar; Corine Chazallon; Francesca Ippolita Calò Carducci; Ursula Trafojer; Ben Abdelkader; Vincent Meiffredy de Cabre; Susanna Esposito; Carlo Giaquinto; Paul T Heath; Mari-Liis Ilmoja; Aspasia Katragkou; Carine Lascoux; Tuuli Metsvaht; George Mitsiakos; Emmanuelle Netzer; Lorenza Pugni; Emmanuel Roilides; Yacine Saidi; Kosmas Sarafidis; Mike Sharland; Vytautas Usonis; Jean-Pierre Aboulker
Journal:  Eur J Pediatr       Date:  2014-02-13       Impact factor: 3.183

4.  Antibiotic regimens for late-onset neonatal sepsis.

Authors:  Steven Kwasi Korang; Sanam Safi; Chiara Nava; Gorm Greisen; Munish Gupta; Ulrik Lausten-Thomsen; Janus C Jakobsen
Journal:  Cochrane Database Syst Rev       Date:  2021-05-08

Review 5.  Late-onset neonatal sepsis: recent developments.

Authors:  Ying Dong; Christian P Speer
Journal:  Arch Dis Child Fetal Neonatal Ed       Date:  2014-11-25       Impact factor: 5.747

6.  Prevalence and nature of off-label antibiotic prescribing for children in a tertiary setting: A descriptive study from Jordan.

Authors:  Tareq L Mukattash; Wail A Hayajneh; Shorok M Ibrahim; Abeer Ayoub; Nehad Ayoub; Anan S Jarab; Maher Khdour; Ammar Almaaytah
Journal:  Pharm Pract (Granada)       Date:  2016-09-15

7.  The first occurrence of a CTX-M ESBL-producing Escherichia coli outbreak mediated by mother to neonate transmission in an Irish neonatal intensive care unit.

Authors:  Ciara O'Connor; Roy K Philip; John Kelleher; James Powell; Alan O'Gorman; Barbara Slevin; Neil Woodford; Jane F Turton; Elaine McGrath; Cathriona Finnegan; Lorraine Power; Nuala H O'Connell; Colum P Dunne
Journal:  BMC Infect Dis       Date:  2017-01-05       Impact factor: 3.090

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.